{"id":6265,"date":"2013-01-29T12:22:00","date_gmt":"2013-01-29T12:22:00","guid":{"rendered":"http:\/\/www.pharma-mkting.com\/in-pre-emptive-strike-amgen-genentec\/"},"modified":"2019-02-21T01:17:57","modified_gmt":"2019-02-21T01:17:57","slug":"in-pre-emptive-strike-amgen-genentec","status":"publish","type":"post","link":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/in-pre-emptive-strike-amgen-genentec\/","title":{"rendered":"In a Pre-emptive Strike, Amgen &#038; Genentech (Roche) Lobby States to Block Biosimilars"},"content":{"rendered":"<p>No doubt you&#8217;ve heard of how Amgen essentially paid off U.S. Senators to sneak a provision in the &#8220;fiscal cliff&#8221; bill that delays price restraints on a class of drugs used by kidney dialysis patients, including Sensipar, a drug made by Amgen (see &#8220;<a href=\"http:\/\/www.forums.pharma-mkting.com\/showthread.php?t=85969\">Big Pharma buys off the Senate<\/a>&#8220;). That &#8220;richly embroidered loophole&#8221; will cost taxpayers a half a billion dollars.<\/p>\n<p>Although a bill was proposed to close the Amgen loophole in federal law, Amgen and Genentech, which is owned by Roche, are lobbying (i.e., paying) state lawmakers to block generic versions of their products according to the New York Times (see <a href=\"http:\/\/www.forums.pharma-mkting.com\/showthread.php?p=89224#post89224\">here<\/a>). Specifically, these companies are proposing bills that would restrict the ability of pharmacists to substitute generic versions of biological drugs for brand name products. &#8220;Bills have been introduced in at least eight states since the new legislative sessions began this month,&#8221; reports the Times. &#8220;Others are pending. The Virginia House of Delegates already passed one such bill last week, by a 91-to-6 vote.&#8221;<\/p>\n<p>These crooks, er&#8230; biotech companies, claim they are doing this in the name of &#8220;patient safety&#8221; because the generic versions of biological drugs (so-called &#8220;biosimilars&#8221;) are not identical to the originals. NOTE: Biosimilars are unlikely to be available in the United States for at least two more years. So, these Biotech lobbying efforts are pre-emptive strikes.<\/p>\n<p>Three of Genentech&#8217;s biologics &#8212; Rituxan, Herceptin and Avastin &#8212; and one of Amgen&#8217;s &#8212; Enbrel &#8212; are among Forbes&#8217; list of &#8220;Best Selling Drugs of All Time&#8221; (see chart below and <a href=\"http:\/\/pharma-mkting.com\/blog\/2013\/01\/lipitor-plavix-last-of-small-molecule.html\">here<\/a>):<\/p>\n<div class=\"separator\" style=\"clear: both; text-align: center;\">\n<a href=\"http:\/\/1.bp.blogspot.com\/-RRw8HNQAqxg\/UQa62JbOQnI\/AAAAAAAAFWA\/Vlv1ykA6l7E\/s1600\/DrugPeakSalesChart.jpg\" imageanchor=\"1\" style=\"margin-left: 1em; margin-right: 1em;\"><img loading=\"lazy\" decoding=\"async\" border=\"0\" height=\"351\" src=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2013\/01\/DrugPeakSalesChart-1.jpg\" width=\"400\" \/><\/a><\/div>\n<p>\n&#8220;These are really complex, highly sensitive molecules,&#8221; said REPUBLICAN State Senator Patricia Vance of Pennsylvania, who plans to introduce a bill. &#8220;We want to make sure we are not hurting people.&#8221; Sure, especially let&#8217;s not hurt the Amgen, Genentech, and Roche stockholders. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>No doubt you&#8217;ve heard of how Amgen essentially paid off U.S. Senators to sneak a provision in the &#8220;fiscal cliff&#8221; bill that delays price restraints on a class of drugs used by kidney dialysis patients, including Sensipar, a drug made by Amgen (see &#8220;Big Pharma buys off the Senate&#8220;). That &#8220;richly embroidered loophole&#8221; will cost [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":11035,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12],"tags":[334,618,445,438,105,157],"topic":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>In a Pre-emptive Strike, Amgen &amp; Genentech (Roche) Lobby States to Block Biosimilars - Pharma Marketing Network<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/in-pre-emptive-strike-amgen-genentec\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"In a Pre-emptive Strike, Amgen &amp; Genentech (Roche) Lobby States to Block Biosimilars - Pharma Marketing Network\" \/>\n<meta property=\"og:description\" content=\"No doubt you&#8217;ve heard of how Amgen essentially paid off U.S. Senators to sneak a provision in the &#8220;fiscal cliff&#8221; bill that delays price restraints on a class of drugs used by kidney dialysis patients, including Sensipar, a drug made by Amgen (see &#8220;Big Pharma buys off the Senate&#8220;). That &#8220;richly embroidered loophole&#8221; will cost [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/in-pre-emptive-strike-amgen-genentec\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Marketing Network\" \/>\n<meta property=\"article:published_time\" content=\"2013-01-29T12:22:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2019-02-21T01:17:57+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2013\/01\/DrugPeakSalesChart-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"400\" \/>\n\t<meta property=\"og:image:height\" content=\"352\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pharma Guy\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pharma Guy\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/in-pre-emptive-strike-amgen-genentec\/\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/in-pre-emptive-strike-amgen-genentec\/\",\"name\":\"In a Pre-emptive Strike, Amgen & Genentech (Roche) Lobby States to Block Biosimilars - Pharma Marketing Network\",\"isPartOf\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website\"},\"datePublished\":\"2013-01-29T12:22:00+00:00\",\"dateModified\":\"2019-02-21T01:17:57+00:00\",\"author\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1\"},\"breadcrumb\":{\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/in-pre-emptive-strike-amgen-genentec\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/in-pre-emptive-strike-amgen-genentec\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/in-pre-emptive-strike-amgen-genentec\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"In a Pre-emptive Strike, Amgen &#038; Genentech (Roche) Lobby States to Block Biosimilars\"}]},{\"@type\":\"WebSite\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/\",\"name\":\"Pharma Marketing Network\",\"description\":\"Pharma Marketing Network\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1\",\"name\":\"Pharma Guy\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/image\/\",\"url\":\"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g\",\"contentUrl\":\"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g\",\"caption\":\"Pharma Guy\"},\"description\":\"Pharmaguy\u2122 is a \u201cconstructive critic\u201d of pharma marketing and publishes commentary on the Pharma Marketing Blog and on Scoop.it.\",\"url\":\"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/author\/ehs-pharmaguy\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"In a Pre-emptive Strike, Amgen & Genentech (Roche) Lobby States to Block Biosimilars - Pharma Marketing Network","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/in-pre-emptive-strike-amgen-genentec\/","og_locale":"en_US","og_type":"article","og_title":"In a Pre-emptive Strike, Amgen & Genentech (Roche) Lobby States to Block Biosimilars - Pharma Marketing Network","og_description":"No doubt you&#8217;ve heard of how Amgen essentially paid off U.S. Senators to sneak a provision in the &#8220;fiscal cliff&#8221; bill that delays price restraints on a class of drugs used by kidney dialysis patients, including Sensipar, a drug made by Amgen (see &#8220;Big Pharma buys off the Senate&#8220;). That &#8220;richly embroidered loophole&#8221; will cost [&hellip;]","og_url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/in-pre-emptive-strike-amgen-genentec\/","og_site_name":"Pharma Marketing Network","article_published_time":"2013-01-29T12:22:00+00:00","article_modified_time":"2019-02-21T01:17:57+00:00","og_image":[{"width":400,"height":352,"url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-content\/uploads\/2013\/01\/DrugPeakSalesChart-1.jpg","type":"image\/jpeg"}],"author":"Pharma Guy","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pharma Guy","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/in-pre-emptive-strike-amgen-genentec\/","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/in-pre-emptive-strike-amgen-genentec\/","name":"In a Pre-emptive Strike, Amgen & Genentech (Roche) Lobby States to Block Biosimilars - Pharma Marketing Network","isPartOf":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website"},"datePublished":"2013-01-29T12:22:00+00:00","dateModified":"2019-02-21T01:17:57+00:00","author":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1"},"breadcrumb":{"@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/in-pre-emptive-strike-amgen-genentec\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/in-pre-emptive-strike-amgen-genentec\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/blog\/in-pre-emptive-strike-amgen-genentec\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/"},{"@type":"ListItem","position":2,"name":"In a Pre-emptive Strike, Amgen &#038; Genentech (Roche) Lobby States to Block Biosimilars"}]},{"@type":"WebSite","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#website","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/","name":"Pharma Marketing Network","description":"Pharma Marketing Network","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/763fc249c59c91ce203db612d81a75a1","name":"Pharma Guy","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/#\/schema\/person\/image\/","url":"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g","contentUrl":"http:\/\/2.gravatar.com\/avatar\/87853617a5e31233716811d09cdefdf7?s=96&d=identicon&r=g","caption":"Pharma Guy"},"description":"Pharmaguy\u2122 is a \u201cconstructive critic\u201d of pharma marketing and publishes commentary on the Pharma Marketing Blog and on Scoop.it.","url":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/author\/ehs-pharmaguy\/"}]}},"_links":{"self":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/6265"}],"collection":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/comments?post=6265"}],"version-history":[{"count":1,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/6265\/revisions"}],"predecessor-version":[{"id":11036,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/posts\/6265\/revisions\/11036"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/media\/11035"}],"wp:attachment":[{"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/media?parent=6265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/categories?post=6265"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/tags?post=6265"},{"taxonomy":"topic","embeddable":true,"href":"http:\/\/ec2-54-175-84-28.compute-1.amazonaws.com\/pharma-mkting.com\/wp-json\/wp\/v2\/topic?post=6265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}